NYSE · NVO
Healthcare · Drug Manufacturers - General
$38.64
Up+$0.46 (+1.20%)
Updated Oct 11, 2026, 2:07 PM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
Price performance · NVO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
NVO closed at $38.64 after 20 trading sessions, down 11.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $38.11 | $38.68 | $38.06 | $38.64 | 9.65M |
| Oct 8, 2026 | $37.80 | $38.23 | $37.505 | $38.18 | 11.82M |
| Oct 7, 2026 | $37.57 | $38.47 | $37.508 | $38.26 | 13.67M |
| Oct 6, 2026 | $37.35 | $37.53 | $36.845 | $37.53 | 13.7M |
| Oct 5, 2026 | $36.94 | $37.61 | $36.855 | $37.54 | 18.7M |
| Oct 2, 2026 | $37.635 | $37.65 | $37.17 | $37.32 | 10.26M |
| Oct 1, 2026 | $37.80 | $37.97 | $37.365 | $37.40 | 12.66M |
| Sep 30, 2026 | $38.05 | $38.77 | $37.885 | $37.91 | 21.56M |
| Sep 29, 2026 | $38.21 | $38.38 | $38.05 | $38.31 | 9.4M |
| Sep 28, 2026 | $38.40 | $38.8984 | $38.2323 | $38.71 | 11.43M |
| Sep 25, 2026 | $38.81 | $38.83 | $38.41 | $38.80 | 10.06M |
| Sep 24, 2026 | $37.95 | $38.7197 | $37.92 | $38.62 | 20.06M |
| Sep 23, 2026 | $38.90 | $39.14 | $38.16 | $38.17 | 18.44M |
| Sep 22, 2026 | $39.50 | $39.89 | $39.105 | $39.40 | 24.46M |
| Sep 21, 2026 | $41.05 | $41.17 | $39.54 | $39.80 | 49.34M |
| Sep 18, 2026 | $43.50 | $43.54 | $42.78 | $43.24 | 10.37M |
| Sep 17, 2026 | $41.98 | $43.44 | $41.96 | $43.19 | 12.95M |
| Sep 16, 2026 | $42.47 | $42.72 | $41.47 | $41.71 | 11.67M |
| Sep 15, 2026 | $42.725 | $43.00 | $42.40 | $42.53 | 8.86M |
| Sep 14, 2026 | $43.66 | $43.71 | $43.0701 | $43.45 | 6.56M |
The latest Smart Investors Daily articles mentioning NVO.
Company
Market Activity
Research & News
NVO research
Company profile and research snapshot.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Hold | — |
| Sep 22, 2026 | BANCO SANTANDER | Outperform | — |
| Sep 22, 2026 | DNB CARNEGIE | Buy | — |
| Sep 22, 2026 | TD COWEN | Hold | — |
Generated Oct 11, 2026, 1:19 PM
Novo Nordisk gained 1.20% today as modest positive momentum offsets recent analyst headwinds and mixed guidance signals. The pharmaceutical giant continues to navigate investor skepticism despite raising its outlook, with the market digesting conflicting signals about its growth trajectory and margin expansion potential.
Bottom line: Novo Nordisk's modest 1.20% gain reflects a stock caught between positive fundamentals (raised guidance, GLP-1 market dominance, clinical catalysts) and legitimate profitability concerns (margin headwinds, analyst price cuts). Investors should monitor upcoming EASD data readouts and FDA decisions closely, while remaining cautious about margin expansion until management demonstrates clear cost control or pricing resilience in competitive markets.
Yahoo · Oct 10, 2026
Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.
Yahoo · Oct 9, 2026
Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook. The shares fell anyway, with investors fixated on pricing pressure and the quality of the beat. Then, at a strategy day in London a few weeks ago, management said it aims to grow revenue through 2030 at roughly the […]
Yahoo · Oct 9, 2026
Citi Research has lowered its price target for Danish pharmaceutical company Novo Nordisk (NYSE:NVO) to DKK 296 from DKK 310, citing limited opportunities for operating margin expansion through 2030 despite improving expectations for sales of its oral obesity treatment, Wegovy. The investment bank maintained its “neutral” rating on the stock following Novo Nordisk’s recent Capital Markets Day, where management indicated that profit margins were expected to remain “broadly stable” over the coming
Yahoo · Oct 9, 2026
Novo Nordisk (CPSE:NOVO B) reported an FDA review update for haemophilia A therapy denecimig, including manufacturing related feedback, in October 2026. The pharmaceutical group presented new CagriSema data on brain and metabolic pathway effects in obesity and diabetes at EASD 2026. Researchers also shared real-world evidence at EASD 2026 comparing clinical outcomes for semaglutide with tirzepatide in everyday practice. Denecimig’s FDA review update and the fresh CagriSema and semaglutide...
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S shares have experienced significant downward pressure across all measured timeframes, with the stock trading at $38.64 per SID market data. The company has declined 12.2% over the past month, 21.59% over three months, and 35.18% over the trailing twelve months, reflecting a pronounced bearish trend for the healthcare giant. NVO currently trades well below both its 50-day moving average of $43.43 and its 200-day moving average of $45.40, confirming sustained negative momentum. The 14-day relative strength index sits at 38.9, approaching oversold territory but not yet triggering a classic oversold signal below 30. Despite this volatility, NVO maintains a beta of just 0.352 per Massive/Polygon data, indicating the stock historically exhibits significantly less sensitivity to broader market movements. Average daily trading volume stands at approximately 16.7 million shares, reflecting robust liquidity amid the selloff.
Novo Nordisk's current valuation metrics reflect a notable compression from historical levels following the stock's steep decline. The company trades at a price-to-earnings ratio of 12.76, per SID market data, which is substantially below the broader healthcare sector average and suggests the market has repriced the company's growth expectations. The PEG ratio stands at 2.05, according to SEC filings, indicating that even when adjusting for anticipated earnings growth, the stock commands a premium relative to a PEG benchmark of 1.0. Novo Nordisk's price-to-book ratio of 8.43 remains elevated, reflecting the asset-light nature of its pharmaceutical business model and significant intangible value tied to its GLP-1 franchise. The company currently offers a dividend yield of 3.66%, which has increased mechanically as the share price has declined. The market capitalization stands at approximately $223.5 billion, positioning NVO among the largest healthcare companies globally.
Smart money indicators for Novo Nordisk present a mixed picture, with an overall composite score of 51 out of 100 and a neutral signal designation, per SID market data. Institutional positioning represents the strongest component, scoring 23.0 out of 25, according to 13F institutional filings, suggesting that major fund managers maintain substantial allocations to the stock despite recent price weakness. Insider activity scores 12.5 out of 25 per SEC Form 4 filings, reflecting a moderate level of insider transactions without a clear directional conviction from company executives and board members. Congressional trading activity registers at 10.4 out of 25, indicating limited but present interest from disclosed legislative portfolio activity. The weakest signal comes from dark pool activity, scoring just 5.0 out of 25, which suggests that off-exchange institutional block trading has been relatively muted. The divergence between strong institutional holdings and weak dark pool activity may indicate that large holders are maintaining positions rather than actively accumulating or distributing shares.
Novo Nordisk's upcoming earnings calendar shows four sequential reporting dates, with analyst consensus estimates reflecting expectations for stable sequential performance, per analyst estimates compiled by SID. The nearest scheduled report on August 21, 2026, carries a consensus earnings estimate of $0.81 per share. The subsequent reports on August 25 and August 28 also carry identical estimates of $0.81 per share, while the November 4 report projects a slight dip to $0.80 per share, according to company earnings reports and consensus forecasts. The tightly clustered estimates across quarters suggest analysts anticipate consistent operational execution without meaningful acceleration or deceleration in the near term. At the current stock price of $38.64 and an implied annualized earnings run rate of approximately $3.23, the forward earnings multiple aligns closely with the trailing P/E of 12.76. No actual results have yet been reported for these periods, leaving potential for estimate revisions ahead of each reporting date.
Recent Wall Street analyst activity on Novo Nordisk reflects a cautiously constructive consensus, with the most recent batch of ratings issued on September 22–23, 2026, per Wall Street analyst reports. Notably, all five covering firms reiterated their prior ratings without changes, suggesting conviction in existing theses despite the stock's significant price decline. Rothschild & Co Redburn and DNB Carnegie both maintained Buy ratings, signaling continued confidence in the company's long-term fundamentals and GLP-1 franchise potential. Banco Santander reiterated its Outperform rating, aligning with the bullish camp. On the more cautious side, Jyske Bank and TD Cowen both maintained Hold ratings, per SID consensus data, reflecting a more reserved stance on near-term catalysts. The split between three bullish ratings and two neutral ratings indicates that the majority of recent covering analysts view the current price decline as a potential opportunity rather than a signal of fundamental deterioration. No analysts issued Sell or Underperform ratings in the latest cycle.
The latest Smart Investors Daily articles mentioning NVO.
